nach oben

Breast Cancer Research

Erschienen in:

01.12.2005 | Review

Overdiagnosis and overtreatment of breast cancer: Rates of ductal carcinoma in situ: a US perspective

verfasst von: Anjali S Kumar, Vinona Bhatia, I Craig Henderson

Erschienen in: Breast Cancer Research | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

The incidence of breast ductal carcinoma in situ (DCIS) in the USA exceeds that of other countries. This cannot be explained entirely by the frequency of mammographic screening in the USA and may result from differences in the interpretation of mammograms and/or the frequency with which biopsies are obtained. Although the percentage of DCIS patients treated with mastectomy has decreased, the absolute number is unchanged and the use of lumpectomy with whole-breast radiotherapy has increased in inverse proportion to the decrease in mastectomy. Treatment of DCIS with tamoxifen is still limited.

Nur mit Berechtigung zugänglich

Recht A, Rutgers EJ, Fentiman IS, Kurtz JM, Mansel RE, Sloane JP: The fourth EORTC DCIS Consensus meeting (Chateau Marquette, Heemskerk, The Netherlands, 23–24 January 1998) – conference report. Eur J Cancer. 1998, 34: 1664-1669. 10.1016/S0959-8049(98)00220-2.CrossRefPubMed

Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R: Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med. 2000, 160: 953-958. 10.1001/archinte.160.7.953.CrossRefPubMed

Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK, (eds): SEER Cancer Statistics Review. 1975, Bethesda, MD: National Cancer Institute, http://seer.cancer.gov/csr/1975_2002/, based on November 2004 SEER data submission, posted to the SEER web site 2005, –2002

Committee on Technologies for the Early Detection of Breast Cancer, Nass SJ, Henderson IC, Lashof JC, (eds): Mammography and Beyond: Developing Technologies for the Early Detection of Breast Cancer. 2001, National Cancer Policy Board, Institute of Medicine, Division of Earth and Life Studies, National Research Council: Washington DC

Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, Yankaskas BC, Rosenberg R, Carney PA, Kerlikowske K, et al: Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002, 94: 1546-1554.CrossRefPubMed

Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, Wolmark N: Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer. 1999, 86: 429-438. 10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO;2-Y.CrossRefPubMed

Baxter NN, Virnig BA, Durham SB, Tuttle TM: Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004, 96: 443-448.CrossRefPubMed

Li CI, Daling JR, Malone KE: Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev. 2005, 14: 1008-1011. 10.1158/1055-9965.EPI-04-0849.CrossRefPubMed

Cooper N, Gautrey M, Quinn M: Cancer Trends in England and Wales, Incidence Data to 2002. 2005, National Cancer Intelligence Centre, Office for National Statistics, [http://www.statistics.gov.uk/statbase/Expodata/Spreadsheets/D8981.xls]

10.

Levi F, Te VC, Randimbison L, La Vecchia C: Trends of in situ carcinoma of the breast in Vaud, Switzerland. Eur J Cancer. 1997, 33: 903-906. 10.1016/S0959-8049(97)00048-8.CrossRefPubMed

11.

US Preventive Services Task Force: Screening for breast cancer: recommendations and rationale. Ann Intern Med. 2002, 137: 344-346.CrossRef

12.

Breast Screening Programme, England: 2003–2004. [http://www.dh.gov.uk/PublicationsAndStatistics/Statistics/StatisticalWorkAreas/StatisticalHealthCare/StatisticalHealthCareArticle/fs/en?CONTENT_ID=4104034&chk=mjJ%2Bof]

13.

Center for Disease Control: 2004, National Center for Health Statistics, United States, [http://www.cdc.gov/nchs/fastats/lifexpec.htm]

14.

Smith-Bindman R, Chu PW, Miglioretti DL, Sickles EA, Blanks R, Ballard-Barbash R, Bobo JK, Lee NC, Wallis MG, Patnick J, et al: Comparison of screening mammography in the United States and the United Kingdom. JAMA. 2003, 290: 2129-2137. 10.1001/jama.290.16.2129.CrossRefPubMed

15.

Elmore JG, Nakano CY, Koepsell TD, Desnick LM, D'Orsi CJ, Ransohoff DF: International variation in screening mammography interpretations in community-based programs. J Natl Cancer Inst. 2003, 95: 1384-1393.CrossRefPubMedPubMedCentral

16.

Fisher B, Costantino J, Redmond C, Fisher E, Margolese R, Dimitrov N, Wolmark N, Wickerham L, Deutsch M, Ore L, et al: Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Eng J Med. 1993, 328: 1581-1586. 10.1056/NEJM199306033282201.CrossRef

17.

Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, Gamagami P, Colburn WJ: The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med . 1999, 340: 1455-1461. 10.1056/NEJM199905133401902.CrossRefPubMed

18.

Ceilley E, Jagsi R, Goldberg S, Kachnic L, Powell S, Taghian A: The management of ductal carcinoma in situ in North America and Europe. Results of a survey. Cancer. 2004, 101: 1958-1967. 10.1002/cncr.20580.CrossRefPubMed

19.

Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, et al: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999, 353: 1993-2000. 10.1016/S0140-6736(99)05036-9.CrossRefPubMed

20.

Yen TW, Hunt KK, Mirza NQ, Thomas ES, Singletary SE, Babiera GV, Meric-Bernstam F, Buchholz TA, Feig BW, Ross MI, et al: Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer. 2004, 100: 942-949. 10.1002/cncr.20085.CrossRefPubMed

21.

NCCN Clinical Practice Guidelines in Oncology – v.2.2005 – Breast Cancer. [http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf]

Titel: Overdiagnosis and overtreatment of breast cancer: Rates of ductal carcinoma in situ: a US perspective
verfasst von: Anjali S Kumar
Vinona Bhatia
I Craig Henderson
Publikationsdatum: 01.12.2005
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe 6/2005
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr1346

Neu im Fachgebiet Onkologie

17.04.2024 | Mammakarzinom | Nachrichten

Springer Medizin

Overdiagnosis and overtreatment of breast cancer: Rates of ductal carcinoma in situ: a US perspective

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2005

A common missense variant in BRCA2 predisposes to early onset breast cancer

CYP17 gene polymorphism in relation to breast cancer risk: a case-control study

CYP2D6 variants and the prediction of tamoxifen response in randomized patients: author response

Allelic imbalances of chromosomes 8p and 18q and their roles in distant relapse of early stage, node-negative breast cancer

Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells

XRCC1 and XPDgenetic polymorphisms, smoking and breast cancer risk in a Finnish case-control study

Neu im Fachgebiet Onkologie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Update Onkologie